Citigroup Initiates Coverage On Krystal Biotech with Buy Rating, Announces Price Target of $160
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Carly Kenselaar has initiated coverage on Krystal Biotech (NASDAQ:KRYS) with a Buy rating and a price target of $160.
October 12, 2023 | 12:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Krystal Biotech has been given a Buy rating by Citigroup with a price target of $160.
The Buy rating and high price target from Citigroup indicate a positive outlook for Krystal Biotech. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100